Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients

Fig. 4

Survival analysis of NSCLC patients with M2 ratio expression according to angiogenesis (VEGF-A) or lymphangiogenesis (VEGF-C) marker expression in NSCLC patients. Dual expression of high M2 ratio and high VEGF-A (M2 ratiohigh/VEGF-Ahigh) exhibited a tendency of worse overall survival (p = 0.056) (a). Survival times for patients with both high M2 ratio and high VEGF-C (M2 ratiohighVEGF-Chigh) expression was significantly shorter (OS rate, 62.2%) than those for patients with M2 ratiolowVEGF-Clow (OS rate, 75.6%), M2 ratiolowVEGF-Chigh (OS rate, 80.6%), and M2 ratiohighVEGF-Clow (OS rate, 73.9%) (log rank p = 0.033) (b)

Back to article page